Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 16:01 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma
NCT05921760 · Servier Bio-Innovation LLC · PHASE1/PHASE2 · terminated · last registry update 2026-04-20 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “The sponsor decided to terminate the study during the safety lead-in phase.” | – | Registry record, Servier Bio-Innovation LLC |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against IDH1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-29Also stopped (withdrawn): Virginia Commonwealth University, Olutasidenib Investigational Agent Administration (NCT07130695)
- 2026-10-05Also stopped (withdrawn): M.D. Anderson Cancer Center, Olutasidenib (NCT06597734)
- 2026-08-04Phase 3 first posted: UNICANCER, Futibatinib + Ivosidenib + Capecitabine (NCT07745296)
- 2026-07-17Phase 3 first posted: Nuvation Bio Inc., Safusidenib + Placebo (NCT07712757)
- 2026-06-01Also stopped (terminated): Northwestern University, Cytarabine + Filgrastim (NCT04250051)
- 2026-04-14Results posted on the registry: National Cancer Institute (NCI), Ensartinib + Erdafitinib (NCT03155620)
- 2026-03-25Results posted on the registry: National Cancer Institute (NCI), Ivosidenib (NCT04195555)
- 2026-01-28Also stopped (withdrawn): Duke University, a drug against IDH1 (NCT06648473)
- 2025-12-09Results posted on the registry: Servier, Ivosidenib (NCT06081829)
- 2025-10-14Phase 3 first posted: Alliance for Clinical Trials in Oncology, Temozolomide + Vorasidenib (NCT07215910)
- 2025-07-20Phase 3 first posted: Stichting Hemato-Oncologie voor Volwassenen Nederland, Venetoclax 400 + Placebo (NCT07075016)
- 2025-06-26Results posted on the registry: Forma Therapeutics, Inc., FT-2102 (olutasidenib) + Azacitidine (NCT02719574)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision